Publikasi Scopus FKUI 2021 per tanggal 31 Juli 2021 (507 artikel)

Mori Y., Sato H., Kumazawa T., Mayang Permata T.B., Yoshimoto Y., Murata K., Noda S.-E., Kaminuma T., Ando K., Oike T., Okonogi N., Okada K., Kakoti S., Suzuki K., Ikota H., Yokoo H., Nakano T., Ohno T., Shibata A.
57210846989;55697961900;57210432294;57215844296;36453407100;36103294900;14621772700;23994005700;55641963900;36453136000;36453127400;57222984111;57197814645;55550919200;57214213081;55588986400;35353843800;35395665700;8323572900;
Analysis of radiotherapy-induced alteration of CD8+ T cells and PD-L1 expression in patients with uterine cervical squamous cell carcinoma
2021
Oncology Letters
21
6
446
Department of Radiation Oncology, Graduate School of Medicine, Gunma University, Maebashi, Gunma, 371-8511, Japan; Department of Radiotherapy, Saitama Cancer Center, Ina, Saitama, 362-0806, Japan; Department of Radiation Oncology, Faculty of Medicine Universitas Indonesia, Dr Cipto Mangunkusumo Hospital, Jakarta, 10430, Indonesia; Department of Radiation Oncology, Fukushima Medical University, Fukushima, 960-1247, Japan; Department of Radiation Oncology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, 350-1298, Japan; National Institute of Radiological Sciences, National Institute for Quantum and Radiological Science and Technology, Chiba, 263-8555, Japan; Signal Transduction Program, Gunma University Initiative for Advanced Research, Gunma University, Maebashi, Gunma, 371-8511, Japan; Department of Radiation Medical Sciences, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, 852-8523, Japan; Clinical Department of Pathology, Gunma University Hospital, Maebashi, Gunma, 371-8511, Japan; Department of Human Pathology, Gunma University, Graduate School of Medicine, Maebashi, Gunma, 371-8511, Japan
Mori, Y., Department of Radiation Oncology, Graduate School of Medicine, Gunma University, Maebashi, Gunma, 371-8511, Japan, Department of Radiotherapy, Saitama Cancer Center, Ina, Saitama, 362-0806, Japan; Sato, H., Department of Radiation Oncology, Graduate School of Medicine, Gunma University, Maebashi, Gunma, 371-8511, Japan; Kumazawa, T., Department of Radiation Oncology, Graduate School of Medicine, Gunma University, Maebashi, Gunma, 371-8511, Japan; Mayang Permata, T.B., Department of Radiation Oncology, Faculty of Medicine Universitas Indonesia, Dr Cipto Mangunkusumo Hospital, Jakarta, 10430, Indonesia; Yoshimoto, Y., Department of Radiation Oncology, Fukushima Medical University, Fukushima, 960-1247, Japan; Murata, K., Department of Radiation Oncology, Graduate School of Medicine, Gunma University, Maebashi, Gunma, 371-8511, Japan; Noda, S.-E., Department of Radiation Oncology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, 350-1298, Japan; Kaminuma, T., Department of Radiation Oncology, Graduate School of Medicine, Gunma University, Maebashi, Gunma, 371-8511, Japan; Ando, K., Department of Radiation Oncology, Graduate School of Medicine, Gunma University, Maebashi, Gunma, 371-8511, Japan; Oike, T., Department of Radiation Oncology, Graduate School of Medicine, Gunma University, Maebashi, Gunma, 371-8511, Japan; Okonogi, N., National Institute of Radiological Sciences, National Institute for Quantum and Radiological Science and Technology, Chiba, 263-8555, Japan; Okada, K., Department of Radiation Oncology, Graduate School of Medicine, Gunma University, Maebashi, Gunma, 371-8511, Japan; Kakoti, S., Department of Radiation Oncology, Graduate School of Medicine, Gunma University, Maebashi, Gunma, 371-8511, Japan, Signal Transduction Program, Gunma University Initiative for Advanced Research, Gunma University, Maebashi, Gunma, 371-8511, Japan; Suzuki, K., Department of Radiation Medical Sciences, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, 852-8523, Japan; Ikota, H., Clinical Department of Pathology, Gunma University Hospital, Maebashi, Gunma, 371-8511, Japan; Yokoo, H., Department of Human Pathology, Gunma University, Graduate School of Medicine, Maebashi, Gunma, 371-8511, Japan; Nakano, T., National Institute of Radiological Sciences, National Institute for Quantum and Radiological Science and Technology, Chiba, 263-8555, Japan; Ohno, T., Department of Radiation Oncology, Graduate School of Medicine, Gunma University, Maebashi, Gunma, 371-8511, Japan; Shibata, A., Signal Transduction Program, Gunma University Initiative for Advanced Research, Gunma University, Maebashi, Gunma, 371-8511, Japan
Radiotherapy induces an immune response in the cancer microenvironment that may influence clinical outcome. The present study aimed to analyse the alteration of CD8+ T-cell infiltration and programmed death-ligand 1 (PD-L1) expression following radiotherapy in clinical samples from patients with uterine cervical squamous cell carcinoma. Additionally, the current study sought to analyse the associa- tion between these immune responses and clinical outcomes. A total of 75 patients who received either definitive chemoradio- therapy or radiotherapy were retrospectively analyzed. CD8+ T-cell infiltration and PD-L1 expression were determined by immunohistochemistry using biopsy specimens before radio- therapy (pre-RT) and after 10 Gy radiotherapy (post-10 Gy). The PD-L1+ rate was significantly increased from 5% (4/75) pre-RT to 52% (39/75) post-10 Gy (P<0.01). Despite this increase in the PD-L1+ rate post-10 Gy, there was no significant association between both pre-RT and post-10 Gy and overall survival (OS), locoregional control (LC) and progression-free survival (PFS). On the other hand, the CD8+ T-cell infiltration density was significantly decreased for all patients (median, 23.1% pre-RT vs. 16.9% post-10 Gy; P=0.038); however, this tended to increase in patients treated with radiotherapy alone (median, 17.7% pre-RT vs. 24.0% post-10 Gy; P=0.400). Notably, patients with high CD8+ T-cell infiltration either pre-RT or post-10 Gy exhibited positive associations with OS, LC and PFS. Thus, the present analysis suggested that CD8+ T-cell infiltration may be a prognostic biomarker for patients with cervical cancer receiving radiotherapy. Furthermore, immune checkpoint inhibitors may be effective in patients who have received radiotherapy, since radiotherapy upregu- lated PD-L1 expression in cervical cancer specimens. © 2021 Spandidos Publications. All rights reserved.
CD8+ T cell; Cervical cancer; Immune modulation; Programmed death-ligand 1; Radiotherapy; Tumor microenvironment
alcohol; biological marker; biotin; cisplatin; citric acid; diaminobenzidine; edetic acid; formaldehyde; hydrogen peroxide; immune checkpoint inhibitor; paraffin; peroxidase; platinum; programmed death 1 ligand 1; streptavidin; adult; aged; antigen retrieval; Article; biopsy; brachytherapy; cancer radiotherapy; cancer staging; CD8+ T lymphocyte; cell density; cell infiltration; chemoradiotherapy; controlled study; diagnostic test accuracy study; down regulation; female; follow up; human; human tissue; immune response; immunohistochemistry; irradiation; lymph node metastasis; major clinical study; microscopy; overall survival; paraffin embedding; progression free survival; protein expression; receiver operating characteristic; retrospective study; room temperature; tumor associated leukocyt
Spandidos Publications
17921074
Article
Q3
766
6367